Table 1.
Study | n | Male/female (% male) | Age, years (S.D.) | SBP, mmHg (S.D.) | DBP, mmHg (S.D.) | BMI, kg/m2 (S.D.) | HTN (%)a | Antihypertensive therapy (%) |
---|---|---|---|---|---|---|---|---|
Discovery meta-analysis (n = 11 816) | ||||||||
InterASIA-1 | 3998 | 1870/2128 (46.8) | 52.5 (7.7) | 140.7 (24.7) | 88.1 (14.8) | 25.2 (3.8) | 61.3 | 26.7 |
Beijing | 466 | 363/103 (77.9) | 51.1 (9.5) | 120.6 (12.8) | 77.9 (8.4) | 24.6 (3.4) | 4.5 | 0 |
GenSalt | 1881 | 993/888 (52.8) | 38.7 (9.5) | 116.9 (14.2) | 73.7 (10.3) | 23.4 (3.2) | 9.8 | 0.4 |
NHAPC | 2893 | 1251/1642 (43.2) | 58.6 (6.0) | 140.2 (22.7) | 80.2 (10.9) | 24.5 (3.6) | 55.0 | 28.3 |
Nanjing | 1146 | 820/326 (71.6) | 59.0 (9.7) | 129.6 (21.1) | 81.0 (10.7) | 23.1 (3.2) | 39.5 | 18.7 |
DFTJ | 1432 | 1118/314 (78.1) | 63.1 (8.1) | 130.0 (18.9) | 78.3 (11.0) | 24.7 (3.3) | 39.8 | 30.8 |
Replication 1 | ||||||||
InterASIA-2 | 12 108 | 5872/6236 (48.5) | 52.6 (8.3) | 136.4 (24.8) | 84.0 (13.5) | 25.0 (3.7) | 48.7 | 20.5 |
Replication 2 | ||||||||
CCHS-1 | 22 896 | 12794/10102 (55.9) | 52.7 (9.5) | 130.3 (21.6) | 80.9 (11.7) | 23.8 (3.5) | 35.5 | 14.0 |
Replication 3 | ||||||||
CCHS-2 | 34 142 | 13199/20943 (38.7) | 52.2 (12.1) | 133.2 (20.1) | 81.4 (11.2) | 24.3 (3.7) | 46.2 | 15.3 |
InterASIA, International Collaborative Study of Cardiovascular Disease in Asia (InterASIA in China); Beijing, Beijing Cardiovascular Risk Factors study; GenSalt, the Genetic Epidemiology Network of Salt-Sensitivity study; NHAPC, The Nutrition and Health of Aging Population in China; Nanjing, Noncommunicable Diseases Screening study in Nanjing; DFTJ, The Dongfeng-Tongji cohort study; CCHS-1, China Cardiovascular Health Study project (Jiangsu); CCHS-2, China Cardiovascular Health Study project (Shandong and Henan); n, sample size; S.D., standard deviation; SBP, systolic blood pressure; DBP, diastolic blood pressure; HTN, hypertension; BMI, body mass index.
Hypertension is defined as SBP ≥140 mmHg and/or DBP ≥90 mmHg or taking antihypertensive medication.